This is a clinical study for adult subjects with Post Traumatic Stress Disorder.
Open label clinical study to evaluate the efficacy of PRX-03140 in reducing PTSD symptoms
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
7
50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.
Sarkis Clinical Trials
Gainesville, Florida, United States
Change in adverse events from baseline
adverse events will be evaluated at every visit
Time frame: weekly for 4 weeks then every 4 weeks until week 14
Change from baseline in PTSD and mood related symptoms
subjects will fill out PTSD and mood related symptoms questionnaires at each visit to show any changes in symptoms from baseline
Time frame: weekly for 4 weeks then every 4 weeks until week 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.